COMPANY
Orthobond
Orthobond develops antimicrobial nanosurfaces that kill bacteria, viruses and fungi mechanically, without antibiotics; its Ostaguard treatment can be applied to implantable devices. From company website Source · Oct 12, 2026
NIH awards 1
- NIH award 1R43AI170418-01 FY2022: $146,428 awarded for that fiscal year; activity R43 (SBIR); PI KATZ, JORDAN; recipient as written: ORTHOBOND CORPORATION, Monmouth Junction, NJ. Development of an Antimicrobial Pedic source ↗
Funding and NIH signals
- SEC Form D raise Raised $8.35M in debt securities (Form D filed Sep 1, 2026). SEC Form D 0001329147-26-000003 (Sep 1, 2026)
Evidence (1 event)
- Sep 1, 2026 · SEC Form D 0001329147-26-000003
Name of Issuer: Orthobond Corp; CIK: 1329147; Address: Monmouth Junction, NJ; Submission type: D; Filing date: 2026-09-01; Industry Group: Other Technology; Date of First Sale: 2026-08-24; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 8346000; Federal exemptions: 06b
- Sep 1, 2026 · SEC Form D 0001329147-26-000003